Anika Therapeutics (ANIK) Leases (2016 - 2025)
Anika Therapeutics (ANIK) has disclosed Leases for 13 consecutive years, with $25.9 million as the latest value for Q4 2025.
- Quarterly Leases rose 0.99% to $25.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.9 million through Dec 2025, up 0.99% year-over-year, with the annual reading at $25.9 million for FY2025, 0.99% up from the prior year.
- Leases for Q4 2025 was $25.9 million at Anika Therapeutics, up from $24.2 million in the prior quarter.
- The five-year high for Leases was $31.6 million in Q2 2022, with the low at $20.5 million in Q1 2022.
- Average Leases over 5 years is $26.3 million, with a median of $26.6 million recorded in 2024.
- The sharpest move saw Leases skyrocketed 47.07% in 2023, then dropped 10.96% in 2025.
- Over 5 years, Leases stood at $21.0 million in 2021, then soared by 46.47% to $30.7 million in 2022, then decreased by 10.24% to $27.6 million in 2023, then decreased by 6.78% to $25.7 million in 2024, then rose by 0.99% to $25.9 million in 2025.
- According to Business Quant data, Leases over the past three periods came in at $25.9 million, $24.2 million, and $24.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.